Application of 82 Sr/ 82 Rb generator in neurooncology.

Autor: Kostenikov NA; Russian Research Center of Radiology and Surgical Technologies (RRCRST) of Ministry of Public Health, Saint-Petersburg, Russia., Zhuikov BL; Institute for Nuclear Research of Russian Academy of Sciences (INR RAS), Moscow, Russia., Chudakov VM; Institute for Nuclear Research of Russian Academy of Sciences (INR RAS), Moscow, Russia., Iliuschenko YR; Russian Research Center of Radiology and Surgical Technologies (RRCRST) of Ministry of Public Health, Saint-Petersburg, Russia., Shatik SV; Russian Research Center of Radiology and Surgical Technologies (RRCRST) of Ministry of Public Health, Saint-Petersburg, Russia., Zaitsev VV; Russian Research Center of Radiology and Surgical Technologies (RRCRST) of Ministry of Public Health, Saint-Petersburg, Russia., Sysoev DS; Russian Research Center of Radiology and Surgical Technologies (RRCRST) of Ministry of Public Health, Saint-Petersburg, Russia., Stanzhevskiy AA; Russian Research Center of Radiology and Surgical Technologies (RRCRST) of Ministry of Public Health, Saint-Petersburg, Russia.
Jazyk: angličtina
Zdroj: Brain and behavior [Brain Behav] 2019 Mar; Vol. 9 (3), pp. e01212. Date of Electronic Publication: 2019 Feb 06.
DOI: 10.1002/brb3.1212
Abstrakt: Introduction: The applicability of "Rubidium Chloride, 82 Rb from Generator" radiopharmaceutical for brain tumors (BT) diagnostics is demonstrated on the basis of the application experience of the radiopharmaceutical in neurooncology.
Experimental: A total of 21 patients with various brain tumors and nonneoplastic abnormal brain masses were investigated.
Results and Discussions: The results of the imaging and differential diagnostics of malignant and benign tumors, nonneoplastic abnormal brain masses and lesions revealed the prevalence of high uptake of the radiopharmaceutical in the malignant tumors in comparison with benign glioma and arteriovenous malformations in which 82 Rb-chloride accumulates in the vascular phase but does not linger further. The ultra-short half-life of radionuclide 82 Rb (76 s) along with a low absorbed radiation dose with 82 Rb-chloride by intravenous administration create a new possibility of successive use of two or more radiopharmaceuticals for the examination of the same patient. For instance, PET examination with 18 F-FDG, 11 C-methionine, 11 C-choline, or any other radiopharmaceutical can be carried out in just 7-15 min. after 82 Rb-chloride injection.
Conclusion: Research demonstrated an effectiveness of 82 Rb-chloride application as a diagnostic agent in neurooncology. A method of dosing and administration of the generator-produced radiopharmaceutical has been worked out. It is possible to do up to 600 PET sessions using one Russian 82 Rb generator GR-01. The generator is proved to be reliable and easy to use. The interest in 82 Rb-chloride as a tumor-seeking radiopharmaceutical rose due to the active application of the modern devices PET/CT in the routine clinical practice.
(© 2019 Institution for Nuclear Research of Russian Academy of Science (INR RAS) Brain and Behavior Published by Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje